Comparative Pharmacology
Head-to-head clinical analysis: DORMATE versus DOXYLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORMATE versus DOXYLAMINE.
DORMATE vs Doxylamine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gamma-aminobutyric acid (GABA) type A receptor positive allosteric modulator; increases chloride ion influx, enhancing inhibitory neurotransmission.
Doxylamine is a first-generation antihistamine with sedative properties. It acts as a competitive antagonist at histamine H1 receptors, thereby blocking the effects of histamine. It also possesses anticholinergic activity.
10 mg orally once daily at bedtime, not to exceed 10 mg/day.
12.5–25 mg orally at bedtime for insomnia; 25 mg orally every 4–6 hours as needed for allergies (max 150 mg/day).
None Documented
None Documented
Terminal elimination half-life 8-12 hours in healthy adults; prolonged in renal impairment (up to 30 hours) and elderly.
Clinical Note
moderateDoxylamine + Venlafaxine
"The risk or severity of adverse effects can be increased when Doxylamine is combined with Venlafaxine."
Clinical Note
moderateDoxylamine + Nefazodone
"The risk or severity of adverse effects can be increased when Doxylamine is combined with Nefazodone."
Clinical Note
moderateDoxylamine + Tranylcypromine
"Doxylamine may increase the anticholinergic activities of Tranylcypromine."
Clinical Note
moderateDoxylamine + Sertraline
10-12 hours; prolonged in elderly and hepatic impairment.
Primarily renal excretion (60-80% as unchanged drug and metabolites); biliary/fecal excretion accounts for 15-25%.
Renal (approximately 60% as unchanged drug and metabolites, primarily as N-desmethyldoxylamine and other metabolites); biliary/fecal (minor).
Category C
Category A/B
Antihistamine (Sedating)
Antihistamine (Sedating)
"The risk or severity of adverse effects can be increased when Doxylamine is combined with Sertraline."